Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria. It is also developing RTX-212 and RTX-4-1BBL for treatment of solid tumors; RTX-212 for hematological cancer; RTX-aAPC to treat solid and hematological cancers; and other product candidates for autoimmune disorders. The company was founded in 2013 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone617-679-9600
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/19/2019 (Estimated)
OptionableNot Optionable
Rubius Therapeutics (NASDAQ:RUBY) Frequently Asked Questions
What is Rubius Therapeutics' stock symbol?
Rubius Therapeutics trades on the NASDAQ under the ticker symbol "RUBY."
How were Rubius Therapeutics' earnings last quarter?
Rubius Therapeutics Inc (NASDAQ:RUBY) announced its quarterly earnings data on Friday, August, 31st. The company reported ($3.33) EPS for the quarter, missing the consensus estimate of ($0.60) by $2.73. During the same period in the prior year, the business earned ($1.25) EPS. View Rubius Therapeutics' Earnings History.
When is Rubius Therapeutics' next earnings date?
What price target have analysts set for RUBY?
4 brokers have issued 12 month price objectives for Rubius Therapeutics' stock. Their forecasts range from $34.00 to $40.00. On average, they anticipate Rubius Therapeutics' stock price to reach $37.00 in the next year. This suggests a possible upside of 107.6% from the stock's current price. View Analyst Price Targets for Rubius Therapeutics.
What is the consensus analysts' recommendation for Rubius Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rubius Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rubius Therapeutics.
Has Rubius Therapeutics been receiving favorable news coverage?
News articles about RUBY stock have trended somewhat positive on Monday, InfoTrie reports. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Rubius Therapeutics earned a news impact score of 1.1 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next few days.
Who are some of Rubius Therapeutics' key competitors?
Some companies that are related to Rubius Therapeutics include Ascendis Pharma A/S (ASND), DiaSorin (DSRLF), Alkermes (ALKS), Penumbra (PEN), Chemed (CHE), Array Biopharma (ARRY), GW Pharmaceuticals PLC- (GWPH), Healthequity (HQY), Hikma Pharmaceuticals (HKMPF), Patheon (PTHN), United Therapeutics (UTHR), GALAPAGOS NV/S (GLPG), Cronos Group (CRON), Novocure (NVCR) and ORION OYJ/ADR (ORINY).
What other stocks do shareholders of Rubius Therapeutics own?
Who are Rubius Therapeutics' key executives?
Rubius Therapeutics' management team includes the folowing people:
- Mr. David R. Epstein, Exec. Chairman (Age 57)
- Dr. Torben Lauesgaard Straight Nissen, Pres (Age 47)
- Dr. Christopher L. Carpenter M.D., Ph.D., Chief Medical Officer (Age 63)
- Dr. Pablo J. Cagnoni, CEO & Director (Age 56)
- Mr. Andrew M. Oh, Chief Financial Officer (Age 47)
When did Rubius Therapeutics IPO?
(RUBY) raised $200 million in an IPO on Wednesday, July 18th 2018. The company issued 9,500,000 shares at $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners served as the underwriters for the IPO.
Who are Rubius Therapeutics' major shareholders?
Rubius Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (8.16%), Baillie Gifford & Co. (5.13%), BlackRock Inc. (3.07%), Jennison Associates LLC (0.60%), Norges Bank (0.57%) and Geode Capital Management LLC (0.25%). View Institutional Ownership Trends for Rubius Therapeutics.
Which institutional investors are selling Rubius Therapeutics stock?
Which institutional investors are buying Rubius Therapeutics stock?
RUBY stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Norges Bank, FMR LLC, Baillie Gifford & Co., California Public Employees Retirement System, Geode Capital Management LLC, Geode Capital Management LLC and Northern Trust Corp. View Insider Buying and Selling for Rubius Therapeutics.
How do I buy shares of Rubius Therapeutics?
Shares of RUBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Rubius Therapeutics' stock price today?
One share of RUBY stock can currently be purchased for approximately $17.82.
How big of a company is Rubius Therapeutics?
Rubius Therapeutics has a market capitalization of $1.41 billion.
What is Rubius Therapeutics' official website?
How can I contact Rubius Therapeutics?
Rubius Therapeutics' mailing address is 325 VASSAR STREET SUITE 1A, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-679-9600 or via email at [email protected]
MarketBeat Community Rating for Rubius Therapeutics (NASDAQ RUBY)
MarketBeat's community ratings are surveys of what our community members think about Rubius Therapeutics and other stocks. Vote "Outperform" if you believe RUBY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RUBY will underperform the S&P 500 over the long term. You may vote once every thirty days.
